Results 181 to 190 of about 868,215 (381)
ABSTRACT Alzheimer's disease (AD) is one of the most common neurological disorders affecting older adults, with approximately 7.2 million cases only in the United States. This number is projected to increase to 13.8 million in the United States by 2060, leading to increased expenditures for healthcare, long‐term care and hospice services. Consequently,
Valentina Zecca +3 more
wiley +1 more source
Abstract Background The pathogenesis and etiology of peri‐implantitis demand a deeper understanding to lead to successful treatment modalities. Animal models of peri‐implantitis pathogenesis offer unique insights but their translational impact requires consideration of implant biomaterials science.
Georgios Kotsakis +15 more
wiley +1 more source
Implementation of a simple dimensionality checking system in Ada 2012 [PDF]
Edmond Schonberg, Vincent Pucci
openalex +1 more source
Abstract Background This first‐in‐human clinical study aimed to evaluate the safety and efficacy of a bioglass incorporated in a toothpaste, in reducing dentin hypersensitivity (DH) compared to a sodium fluoride (NaF) toothpaste over a 2‐week period. Methods A double‐blind, randomized, parallel‐arm, proof‐of‐concept clinical trial was conducted with 46
Hatice Hasturk +6 more
wiley +1 more source
Abstract Objectives The increasing incidence of inflammatory bowel disease (IBD) in paediatric populations underscores the importance of effective management strategies. Anti–tumor necrosis factor (anti‐TNF) agents, such as infliximab (IFX) and adalimumab (ADL), are key treatments for inducing and maintaining remission in IBD, but many patients ...
Karlotta Pauline Hubert +2 more
wiley +1 more source
Resistance training and subcortical vascular cognitive impairment: A 12-month randomized trial. [PDF]
Liu-Ambrose T +13 more
europepmc +1 more source
Abstract Objectives 5‐Aminosalicylic acid (5‐ASA) is recommended as a first‐line medication in mild to moderate ulcerative colitis (UC), but indications regarding its use in children with moderate to severe disease treated with biologics are lacking.
Giulia D'Arcangelo +12 more
wiley +1 more source
Abstract Ustekinumab (UST) is a monoclonal antibody used in the management of moderate to severe inflammatory bowel disease. While generally well‐tolerated, serious adverse reactions, including hypersensitivity and anaphylaxis, have been documented, specifical following the initial intravenous (IV) dose.
Kennedy Sparling +2 more
wiley +1 more source

